Female sexual dysfunction (FSD) affects up to 43% of women at some point in their lives, yet it remains significantly undertreated compared to male sexual dysfunction. PT-141 (Bremelanotide) — a melanocortin receptor agonist — offers a unique mechanism for addressing FSD that targets the central nervous system rather than the vascular system, making it effective for the neurological and hormonal components of female sexual response.
The Melanocortin Mechanism
PT-141 activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, which are directly involved in regulating sexual arousal and desire. Unlike PDE5 inhibitors (which work on vascular smooth muscle), PT-141 works upstream — at the level of the brain — to initiate the neurological cascade that drives sexual desire and arousal.
FDA Approval and Clinical Evidence
PT-141 (as Bremelanotide/Vyleesi) received FDA approval in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the very few peptides with formal FDA approval for a women's health indication. Clinical trials demonstrated significant improvements in sexual desire and reductions in distress related to low sexual desire.
Menopause-Related Sexual Dysfunction
Menopause-related sexual dysfunction is driven by multiple factors: declining estrogen (causing vaginal atrophy and reduced lubrication), declining testosterone (reducing libido), and neurological changes affecting arousal. PT-141's central mechanism of action addresses the neurological component directly, making it complementary to estrogen-based therapies that address the peripheral components.